2001 Heart and Stroke Statistical Update . Dallas, Tex: American Heart Association; 2000.
The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary
heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet.1994;344:1383-1389.
Shepherd J, Cobbe SM, Ford I.
et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease in men with hypercholesterolemia. N Engl J Med.1995;333:1301-1307.
Sacks FM, Pfeffer MA, Moye LA.
et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction
in patients with average cholesterol levels. N Engl J Med.1996;335:1001-1009.
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group. Prevention of cardiovascular events and death with pravastatin in patients
with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med.1998;339:1349-1357.
Downs JR, Clearfield M, Weis S.
et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men
and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA.1998;279:1615-1622.
MRC/BHF Heart Protection Study. Preliminary results. Available at: http://www.hpsinfo.org/. Accessed November
Miettinen TA, Pyorala K, Olsson AG.
et al. Cholesterol-lowering therapy in women and elderly patients with myocardial
infarction or angina pectoris: findings from the Scandinavian Simvastatin
Survival Study (4S). Circulation.1997;96:4211-4218.
Hunt D, Young P, Simes J.
et al. Benefits of pravastatin on cardiovascular events and mortality in older
patients with coronary heart disease are equal to or exceed those seen in
younger patients: results from the LIPID trial. Ann Intern Med.2001;134:931-940.
Lewis SJ, Moye LA, Sacks FM.
et al. Effect of pravastatin on cardiovascular events in older patients with
myocardial infarction and cholesterol levels in the average range: results
of the Cholesterol and Recurrent Events (CARE) Trial. Ann Intern Med.1998;129:681-689.
Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary
prevention lipid-lowering drug therapy. Circulation.2002;105:152.
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA.2001;285:2486-2497.
Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction. Arch Intern Med.2001;161:183-188.
McCormick D, Gurwitz JH, Lessard D.
et al. Use of aspirin, β-blockers, and lipid-lowering medications before
recurrent acute myocardial infarction. Arch Intern Med.1999;159:561-567.
Lemaitre RN, Furberg CD, Newman AB.
et al. Time trends in the use of cholesterol-lowering agents in older adults:
the Cardiovascular Health Study. Arch Intern Med.1998;158:1761-1768.
Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary
artery disease. J Gen Intern Med.1999;14:711-717.
Schwed A, Fallab CL, Burnier M.
et al. Electronic monitoring of compliance to lipid-lowering therapy in clinical
practice. J Clin Pharmacol.1999;39:402-409.
Eriksson M, Hadell K, Holme I.
et al. Compliance with and efficacy of treatment with pravastatin and cholestyramine. J Intern Med.1998;243:373-380.
Avorn J, Monette J, Lacour A.
et al. Persistence of use of lipid-lowering medications: a cross-national
Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering
drugs. Med J Aust.1996;164:208-211.
Andrade SE, Walker AM, Gottlieb LK.
et al. Discontinuation of antihyperlipidemic drugs—do rates reported
in clinical trials reflect rates in primary care settings? N Engl J Med.1995;332:1125-1131.
Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications. Am J Manag Care.1999;5:437-444.
Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical
diseases. N Engl J Med.1998;338:1516-1520.
Rudd P. Compliance with antihypertensive therapy: a shifting paradigm. Cardiol Rev.1994;2:230-240.
Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med.1997;241:317-325.
Monane M, Bohn RL, Gurwitz JH.
et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees. Am J Public Health.1996;86:1805-1808.
Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive
therapy compliance. Am J Hypertens.1997;10:697-704.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal
studies: development and validation. J Chronic Dis.1987;40:373-383.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative
databases. J Clin Epidemiol.1992;45:613-619.
Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika.1986;73:13-22.
SAS version 8.2. Cary, NC: SAS Institute Inc; 2000.
Choo PW, Rand CS, Inui TS.
et al. Validation of patient reports, automated pharmacy records, and pill
counts with electronic monitoring of adherence to antihypertensive therapy. Med Care.1999;37:846-857.
Gurwitz JH, Glynn RJ, Monane M.
et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health.1993;83:711-716.
Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med.1994;154:2109-2110.
Wang PJ, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive
symptoms and psychosocial factors. J Gen Intern Med.In press.
La Rosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized
controlled trials. JAMA.1999;282:2340-2346.
Jackevicius CA, Anderson GM, Leiter L, Vu JV. Use of the statins in patients after acute myocardial infarction: does
evidence change practice? Arch Intern Med.2001;161:183-188.
Brier KL, Tornow JJ, Ries AJ, Weber MP, Downs JR. Forecasting patient outcomes in the management of hyperlipidemia. Arch Intern Med.1999;159:569-575.
Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients
to follow prescriptions for medications. Lancet.1996;348:383-386.
Burke LE, Dunbar-Jacob JM, Hill MN. Compliance with cardiovascular disease prevention strategies: a review
of the research. Ann Behav Med.1997;19:239-263.
Roter DL, Hall JA, Merisca R.
et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care.1998;36:1138-1161.